The size of the Leukemia Therapeutics market in the Middle-East and Africa has been estimated at USD 0.59 Billion in 2022 and is projected to reach USD 0.92 Billion by 2027, at a CAGR of 9.23% during the forecast period from 2022 to 2027.
Leukemia is a type of cancer where abnormal white blood cells crowd the bone marrow and other organs such as the liver, spleen, and kidneys through blood and prevent its normal functions. It is commonly caused due to the high exposure to radiation, an unhealthy lifestyle, genetic factors, and environmental conditions. It is common in adults and is observed to progress with aging.
The factor that is driving the market for Leukemia Therapeutics in Middle-east and Africa is the simultaneous increase in increasing awareness about cancer treatments and drugs, along with increasing occurrence. Also, due to the increasing aging population, the market is driven, as the disease is common with aging.
But the market is feared to decline due to the high costs of treatment and drugs.
This research report on the MEA Leukemia Therapeutics Market has been segmented and sub-segmented into the following categories
By Disease Condition:
By disease condition, chronic myeloid leukemia dominated the overall therapeutic market owing to the high prevalence rate. Stem cell therapy and bone marrow transplant are the emerging trends in the leukemia therapeutics market. Gleevec was one of the major market growth contributors, in the drugs category.
Factors such as the rising prevalence of Leukemia, growing awareness of cancer screening programs, and raising awareness for healthcare among the population in developing nations of the region are making the companies penetrate into this market.
The leading companies leading in the MEA Leukemia Therapeutics market profiled in the report are F.Hoffmann-La Roche Ltd, GlaxoSmithKline Pharmaceuticals Limited, Novartis International AG, Bristol-Myers Squibb, Eisai Co. Ltd, Biogen Idec, ERYtech Pharma, Celgene Corporation, Genmab A/S, Cephalon Inc., Clavis Pharma, and Pfizer Inc.
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: email@example.com